Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial

Exploring the Underlying Mechanism of Shenyankangfu Tablet in the Treatment of Glomerulonephritis Through Network Pharmacology, Machine Learning, Molecular Docking, and Experimental Validation

“…Previous studies have shown that SYKFT can alleviate proteinuria, and the effect improves with the prolongation of medication time, indicating that the SYKFT mechanism differs from that of RAS inhibitors. 5 In the present study, herb-target network analysis on the active ingredient indicated that quercetin, kaempferol, arachidonic acid, luteolin, naringenin, and other active ingredients could act as multiple targets in the network and may play important roles in GN treatment under the SYKFT mechanism. Quercetin possesses the most potential targets; kaempferol comes second, followed by arachidonic acid, luteolin, and naringenin.…”

“…The use of combined SYKFT and losartan potassium could exert stronger effects of proteinuria reduction than the use of losartan potassium. 5 However, the potential mechanism of SYKFT for GN treatment remains unclear. The study aimed to predict the targets and signaling pathways of SYKFT for GN treatment under network pharmacology and to further clarify the potential mechanism of SYKFT for GN treatment.…”

“…Figure5 Topological analysis of the protein-protein interaction network to identify the core targets (A). Herb-active ingredients-target network of core targets (B).…”

Beneficial effects of procyanidin B2 on adriamycin-induced nephrotic syndrome mice: the multi-action mechanism for ameliorating glomerular permselectivity injury

“…70 Therefore, SIR remains one of the common positive controls in nephropathy-related drug studies. 71,72 Given the pleiotropic reno-protective effects of SIR on kidney injury, we chose to use SIR as a positive control. Herein, SIR exhibited a protective effect on ADR-induced kidney injury by suppressing oxidative distress, inflammatory responses, and apoptosis in NS mice, similar to previous findings.…”

Use of bailing capsules (cordyceps sinensis) in the treatment of chronic kidney disease: a meta-analysis and network pharmacology

“…With the advancement of TCM, numerous studies at the molecular level have also provided substantial evidence for the efficacy and mechanisms of TCM (Lu et al, 2019;Ma et al, 2023). For example, in the recently published RCT study of Shenyankangfu Tablet in the treatment of primary glomerulonephritis, Shenyankangfu Tablet decreased the proteinuria (Wu et al, 2021). And Huangkui Capsule (HKC) may reduce podocyte damage to ameliorate proteinuria via JAK2/STAT3 and PI3K/Akt pathway (Zhao et al, 2023).…”